Search for: "AKTIEBOLAGET HASSLE"
Results 1 - 8
of 8
Sorted by Relevance
|
Sort by Date
8 Dec 2013, 8:02 pm
Aurobindo Pharma Ltd. et al. 3:13-cv-07298; filed December 3, 2013 in the District Court of New Jersey • Plaintiffs: Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI Inc.; KBI-E Inc. [read post]
25 Mar 2012, 9:25 pm
Mylan Laboratories Ltd, et al. 3:12-cv-01378; filed March 6, 2012 in the District Court of New Jersey • Plaintiffs: Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI... [read post]
7 Aug 2011, 8:36 pm
., Unit III et al. 3:11-cv-04468; filed August 2, 2011 in the District Court of New Jersey • Plaintiffs: Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI Inc.; KBI-E Inc. [read post]
24 Mar 2013, 8:01 pm
. - Florida et al. 3:13-cv-01669; filed March 19, 2013 in the District Court of New Jersey • Plaintiffs: AstraZeneca AB; Aktiebolaget Hassle; AstraZeneca LP; KBI Inc.; KBI-E Inc. [read post]
12 Jun 2008, 4:45 am
Omeprazole is the active ingredient in Prilosec ®, which is marketed by Plaintiffs-Appellants Astrazeneca, AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP (Astrazeneca) for the treatment of gastric and duodenal ulcers, and which acts by inhibiting the production of gastric acid. [read post]
21 Jan 2010, 6:32 pm
Secondly, since the landmark High Court decision in Aktiebolaget Hassle v Alphapharm Pty Ltd [2002] HCA 59, “obvious to try” does not make an invention obvious in Australia. [read post]
18 Jan 2010, 6:30 am
Rather, in order to be citable, a prior art reference must firstly be shown to be a piece of prior art information that the skilled person could have been reasonably expected to have “ascertained, understood, and regarded as relevant”.Secondly, since the landmark High Court decision in Aktiebolaget Hassle v Alphapharm Pty Ltd [2002] HCA 59, “obvious to try” does not make an invention obvious in Australia. [read post]
15 Feb 2011, 9:27 am
Michael Davitz, Partner at Axinn, Veltrop & Harkrider and Practice Center Contributor, recently sent in this article he wrote with colleague’s Drew Schulte and Jia Li discussing the Patent Prosecution Highway and the value that can be achieved for those practitioners willing to explore the new program. [read post]
